Research programme: MEK kinase inhibitors - Array BioPharma

Drug Profile

Research programme: MEK kinase inhibitors - Array BioPharma

Alternative Names: AR 00241389; ARRY-241389

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Novartis
  • Class Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 13 Jul 2010 Preclinical development is ongoing in USA
  • 21 Apr 2010 Array BioPharma enters into a worldwide agreement with Novartis for the development of small-molecule MEK inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top